Follow us @BoneJointRes

Freely available online OPEN ACCESS

BJR

EDITORIAL

Antimicrobial rationing in orthopaedic surgery

S-T. J. Tsang, A. H. R. W. Simpson

From University of Edinburgh, Edinburgh, UK

Cite this article: *Bone Joint Res* 2020;9(12):870–872.

Keywords: Antimicrobials, Antimicrobial resistance, Antimicrobial rationing

The use of prophylactic systemic antibiotics in the perioperative period has been shown to reduce postoperative infections following arthroplasty procedures,[1,2] tumour surgery,[3] and trauma procedures.[4] In open fractures, the administration of systemic broad-spectrum antibiotics has been shown to be a more important factor in minimizing the risk of infection than timing of surgical debridement.[5,6] Local antibiotic prophylaxis using bone cement has been shown to reduce the risk of deep postoperative infection following arthroplasty surgery significantly.[7-9] More recently a systematic review and meta-analysis found that local antibiotic prophylaxis resulted in a four-fold relative risk reduction in fracture-related infection following open limb injury.[10] The World Health Organization (WHO) recommends preoperative screening and eradication in orthopaedic surgery of not only methicillin-resistant *Staphylococcus aureus* (MRSA) but methicillin-sensitive *S. aureus* (MSSA).[11] Evaluation of these strategies has shown them to be both effective[12-15] and acceptable to patients.[16] An economic analysis estimated that national *S. aureus* screening programmes could potentially save up to $900 million in total treatment costs annually in the USA and UK.[17]

Even with therapeutic antibiotic use there has been an evolution in practice. The administration of combination therapies (local and systemic routes) has become more popular, despite the paucity of published evidence. Combination therapies are thought to work by: 1) broadening the spectrum of activity; 2) utilizing synergistic effects; 3) preventing resistance mechanisms from evolving; 4) enhancing intracellular penetration; and 5) limiting the expression of bacterial toxins and other virulence factors.[18] Meta-analyses of clinical trials evaluating antibiotic combinations in periprosthetic joint infection (PJI) have reported that the available literature is currently too heterogeneous to draw any clinically useful conclusions regarding optimal regimens.[19,20] Yang et al[21] have compared the effectiveness of a gentamicin and vancomycin (GV)-loaded articulating spacer in two-stage revision with a vancomycin, meropenem, and amphotericin (VMA)-loaded cement spacer. It was postulated that a high percentage of gentamicin resistance within cultured isolates (22/78) was the reason the VMA combination was found to be more effective at eradicating PJI (11/62 vs 1/52). However, it should be noted that from the preoperative and intraoperative samples 20/62 and 9/52 cases were culture-negative in the full GV and in full VMA protocols, respectively, despite fulfilling the Musculoskeletal Infection Society (MSIS) criteria for PJI.[22] One explanation for these culture-negative samples could be the presence of viable but non-culturable pathogens. This is a cellular state characterized by low metabolic activity and failure to grow on routine bacteriological media.[23] Known inducers of the viable but non-culturable state include: starvation; non-physiological ambient temperature; osmotic stress; hypoxia; heavy metals; and antimicrobial and disinfectant challenges.[24-27] A critical feature is that nutritional stimulation, known as resuscitation in this field of microbiology, can restore metabolic activity and culturability.[25,28] It has been hypothesized that in vivo resuscitation of quiescent cells may be responsible for recalcitrant biomaterial infections.[29] The biofilm phenotype, as often displayed by common biomaterial pathogens, is physiologically akin to the viable but non-culturable state, therefore inadequate resuscitation during laboratory culture may result in false negative results.[30] The phenomenon of viable but non-culturable

Correspondence should be sent to Shao-Ting Jerry Tsang; email: jerry.tsang@ed.ac.uk

doi: 10.1302/2046-3758.912.BJR-2020-0521

Bone Joint Res 2020;9(12):870–872.

states should therefore be taken into account when considering whether infection has been eradicated.

The looming global crisis of antimicrobial resistance[31,32] threatens to halt elective biomaterial-associated procedures.[33,34] Careful antimicrobial stewardship is essential to decelerate the emergence of resistance to currently available drugs, and thus preserve their efficacy. One approach is to explore alternative bactericidal agents for the treatment of biomaterial-associated infections.[35-41] A further approach is to implement antimicrobial stewardship interventions. Evaluations of these interventions have demonstrated their efficacy in reducing rates of both infection and colonization with antimicrobial-resistant bacteria.[42-44] The prevalence of carbapenem (e.g. meropenem)[45,46] and glycopeptides (e.g. vancomycin)[47,48] resistance is increasing globally and their use should be restricted, unless absolutely necessary, to maintain their efficacy. The WHO recognizes carbapenems and glycopeptides as 'critically important' antimicrobials.[49] Carbapenem and glycopeptide sparing, when clinically and microbiologically appropriate, is therefore a key goal of antimicrobial stewardship programmes. The injudicious use of critically important antimicrobials should be questioned.[50] Their incorporation into local treatment protocols should only be implemented following a review of the institution's bacterial epidemiology and justified by local resistance profiles as carried out by Yang et al.[21]

Twitter

Follow S-T. J. Tsang @drjerrytsang
Follow A. H. R. W. Simpson @ahrwsimpson

References

1. **AlBuhairan B**, **Hind D**, **Hutchinson A**. Antibiotic prophylaxis for wound infections in total joint arthroplasty. *J Bone Joint Surg Br*. 2008;90-B(7):915–919.
2. **Lidwell OM**, **Lowbury EJ**, **Whyte W**, **Blowers R**, **Stanley SJ**, **Lowe D**. Infection and sepsis after operations for total hip or knee-joint replacement: influence of ultraclean air, prophylactic antibiotics and other factors. *J Hyg*. 1984;93(3):505–529.
3. **PARITY Investigators**. Prophylactic antibiotic regimens in tumour surgery (parity): a pilot multicentre randomised controlled trial. *Bone Joint Res*. 2015;4(9):154–162.
4. **Boxma H**, **Broekhuizen T**, **Patka P**, **Oosting H**. Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: the Dutch trauma trial. *Lancet*. 1996;347(9009):1133–1137.
5. **Patzakis MJ**, **Wilkins J**. Factors influencing infection rate in open fracture wounds. *Clin Orthop Relat Res*. 1989(243):36–40.
6. **Lack WD**, **Karunakar MA**, **Angerame MR**, **et al**. Type III open tibia fractures: immediate antibiotic prophylaxis minimizes infection. *J Orthop Trauma*. 2015;29(1):1–6.
7. **Espehaug B**, **Engesaeter LB**, **Vollset SE**, **Havelin LI**, **Langeland N**, **Surgeon O**. Antibiotic prophylaxis in total hip arthroplasty. review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. *J Bone Joint Surg Br*. 1997;79-B(4):590–595.
8. **Thierse L**. [Experiences with Refobacin-Palacos with regard to deep late infections following hip-joint endoprosthesis surgery. A 4-years' study (author's transl)]. *Z Orthop Ihre Grenzgeb*. 1978;116(6):847–852. (Article in German)
9. **Chiu F-Y**, **Chen C-M**, **Lin C-FJ**, **Lo W-H**. Cefuroxime-impregnated cement in primary total knee arthroplasty: a prospective, randomized study of three hundred and forty knees. *J Bone Joint Surg Am*. 2002;84-A(5):759–762.
10. **Morgenstern M**, **Vallejo A**, **McNally MA**, **et al**. The effect of local antibiotic prophylaxis when treating open limb fractures. *Bone Joint Res*. 2018;7:447–456.
11. **Allegranzi B**, **Bischoff P**, **de Jonge S**, **et al**. New who recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis*. 2016;16(12):e276–e287.
12. **Ammerlaan HSM**, **Kluytmans JAJW**, **Wertheim HFL**, **Nouwen JL**, **Bonten MJM**. Eradication of methicillin-resistant *Staphylococcus aureus* carriage: a systematic review. *Clin Infect Dis*. 2009;48(7):922–930.
13. **Bode LGM**, **Kluytmans JAJW**, **Wertheim HFL**, **et al**. Preventing surgical-site infections in nasal carriers of *Staphylococcus aureus*. *N Engl J Med*. 2010;362(1):9–17.
14. **Dancer SJ**, **Christison F**, **Eslami A**, **et al**. Is it worth screening elective orthopaedic patients for carriage of *Staphylococcus aureus*? A part-retrospective case-control study in a Scottish Hospital. *BMJ Open*. 2016;6(9):e011642.
15. **Jeans E**, **Holleyman R**, **Tate D**, **Reed M**, **Malviya A**. Methicillin sensitive Staphylococcus aureus screening and decolonisation in elective hip and knee arthroplasty. *J Infect*. 2018;77(5):405–409.
16. **Tsang STJ**, **McHugh MP**, **Guerendiain D**, **et al**. Evaluation of Staphylococcus aureus eradication therapy in orthopaedic surgery. *J Med Microbiol*. 2018;67(6):893–901.
17. **Tsang STJ**, **McHugh MP**, **Guerendiain D**, **et al**. Underestimation of Staphylococcus aureus (MRSA and MSSA) carriage associated with standard culturing techniques: one third of carriers missed. *Bone Joint Res*. 2018;7(1):79–84.
18. **Dall GF**, **Tsang S-TJ**, **Gwynne PJ**, **et al**. Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms. *J Antimicrob Chemother*. 2018;73(7):1830–1840.
19. **Stengel D**, **Bauwens K**, **Sehouli J**, **Ekkernkamp A**, **Porzsolt F**. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. *Lancet Infect Dis*. 2001;1(3):175–188.
20. **Iarikov D**, **Demian H**, **Rubin D**, **Alexander J**, **Nambiar S**. Choice and doses of antibacterial agents for cement spacers in treatment of prosthetic joint infections: review of published studies. *Clinical Infectious Diseases*. 2012;55(11):1474–1480.
21. **Yang C**, **Wang J**, **Yin Z**, **et al**. A sophisticated antibiotic-loading protocol in articulating cement spacers for the treatment of prosthetic joint infection: a retrospective cohort study. *Bone Joint Res*. 2019;8(11):526–534.
22. **Parvizi J**, **Zmistowski B**, **Berbari EF**, **et al**. New definition for periprosthetic joint infection: from the Workgroup of the musculoskeletal infection Society. *Clin Orthop Relat Res*. 2011;469(11):2992–2994.
23. **Oliver JD**. The public health significance of viable but nonculturable bacteria. *Nonculturable Microorganisms in the Environment*. 2020:277–300.
24. **Oliver JD**. Recent findings on the viable but nonculturable state in pathogenic bacteria. *FEMS Microbiol Rev*. 2010;34(4):415–425.
25. **Kana BD**, **Gordhan BG**, **Downing KJ**, **et al**. The resuscitation-promoting factors of *Mycobacterium tuberculosis* are required for virulence and resuscitation from dormancy but are collectively dispensable for growth *in vitro*. *Mol Microbiol*. 2008;67(3):672–684.
26. **Trevors JT**. Viable but non-culturable (VBNC) bacteria: gene expression in planktonic and biofilm cells. *J Microbiol Methods*. 2011;86(2):266–273.
27. **Pasquaroli S**, **Zandri G**, **Vignaroli C**, **Vuotto C**, **Donelli G**, **Biavasco F**. Antibiotic pressure can induce the viable but non-culturable state in Staphylococcus aureus growing in biofilms. *J Antimicrob Chemother*. 2013;68(8):1812–1817.
28. **Dworkin J**, **Shah IM**. Exit from dormancy in microbial organisms. *Nat Rev Microbiol*. 2010;8(12):890–896.
29. **Zandri G**, **Pasquaroli S**, **Vignaroli C**, **et al**. Detection of viable but non-culturable staphylococci in biofilms from central venous catheters negative on standard microbiological assays. *Clin Microbiol Infect*. 2012;18(7):E259–E261.
30. **Tsang S-TJ**, **Eyre DW**, **Simpson AHRW**, **Simpson AHRW**. Should modern molecular testing be routinely available for the diagnosis of musculoskeletal infection? *Bone Joint J*. 2020;102-B(10):1274–1276.
31. **World Health Organization**. Surveillance of antimicrobial resistance for local and global action. 2014. http://www.who.int/drugresistance/events/SwedenMeeting/en/. (date last accessed 1 December 2014).
32. **Li B**, **Webster TJ**. Bacteria antibiotic resistance: new challenges and opportunities for implant-associated orthopedic infections. *J Orthop Res*. 2018;36(1):22–32.
33. **O'Neill J**. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf (date last accessed 7 December 2020).
34. **Davies S**. Antimicrobial resistance poses 'catastrophic threat', says Chief Medical Officer - GOV.UK. Department of Health and Social Care. 2013. https://www.gov.uk/government/news/antimicrobial-resistance-poses-catastrophic-threat-says-chief-medical-officer--2. (date last accessed 11 March 2019).

35. **Deng Z**, **Liu F**, **Li C**. Therapeutic effect of ethylenediaminetetraacetic acid irrigation solution against wound infection with drug-resistant bacteria in a rat model: an animal study. *Bone Joint Res.* 2019;8(5):189–198.
36. **Tsang STJ**, **Gwynne PJ**, **Gallagher MP**, **Simpson AHRW**. The biofilm eradication activity of acetic acid in the management of periprosthetic joint infection. *Bone Joint Res.* 2018;7(8–517–523.
37. **Pijls BG**, **Sanders IMJG**, **Kuijper EJ**, **Nelissen RGHH**. Segmental induction heating of orthopaedic metal implants. *Bone Joint Res.* 2018;7(11):609–619.
38. **Pijls BG**, **Sanders IMJG**, **Kuijper EJ**, **Nelissen RGHH**. Non-contact electromagnetic induction heating for eradicating bacteria and yeasts on biomaterials and possible relevance to orthopaedic implant infections. *Bone Joint Res.* 2017;6(5):323–330.
39. **Hernandez P**, **Sager B**, **Fa A**, **Liang T**, **Lozano C**, **Khazzam M**. Bactericidal efficacy of hydrogen peroxide on *Cutibacterium acnes*. *Bone Joint Res.* 2019;8(1):3–10.
40. **Alt V**, **Rupp M**, **Lemberger K**, **et al**. Safety assessment of microsilver-loaded poly(methyl methacrylate) (PMMA) cement spacers in patients with prosthetic hip infections: Results of a prospective cohort study. *Bone Joint Res.* 2019;8:387–396.
41. **Tsang S-TJ**, **Morgan-Jones R**, **Simpson AHRW**. Debridement for prosthetic joint infections: future therapies. *Bone Joint Res.* 2020;9(6):311–313.
42. **Davey P**, **Marwick CA**, **Scott CL**, **et al**. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev.* 2017;2(5):CD003543.
43. **Baur D**, **Gladstone BP**, **Burkert F**, **et al**. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. *Lancet Infect Dis.* 2017;17(9):990–1001.
44. **Russell CD**, **Laurenson IF**, **Evans MH**, **Mackintosh CL**. Tractable targets for meropenem-sparing antimicrobial stewardship interventions. *JAC Antimicrob Resist.* 2019;1(2).
45. **Livorsi DJ**, **Chorazy ML**, **Schweizer ML**, **et al**. A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States. *Antimicrob Resist Infect Control.* 2018;7(1):55.
46. **van Duin D**, **Doi Y**. The global epidemiology of carbapenemase-producing Enterobacteriaceae. *Virulence.* 2017;8(4):460–469.
47. **Ruef C**. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. *Infection.* 2004;32(6):315–327.
48. **Faron ML**, **Ledeboer NA**, **Buchan BW**. Resistance mechanisms, epidemiology, and approaches to screening for vancomycin-resistant Enterococcus in the health care setting. *J Clin Microbiol.* 2016;54(10):2436–2447.
49. **World Health Organization**. *Critically important antimicrobials for human medicine, 6th revision*. WHO, 2019.
50. **Stravinskas M**, **Nilsson M**, **Vitkauskiene A**, **Tarasevicius S**, **Lidgren L**. Vancomycin elution from a biphasic ceramic bone substitute. *Bone Joint Res.* 2019;8(2):49–54.

Author information:
- S-T. J. Tsang, BSc (Hons), MBChB, MSc, MRCSEd, Orthopaedic Registrar, Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh, UK; Department of Trauma and Orthopaedics, Royal Infirmary of Edinburgh, Edinburgh, UK.
- A. H. R. W. Simpson, MA(Cantab), DM (Oxon), FRCS (England & Edinburgh), George Harrison Law Professor of Orthopaedic Surgery, Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh, UK.

Author contributions:
- S-T. J. Tsang: Conceptualized, co-authored, and edited the manuscript.
- A. H. R. W Simpson: Conceptualized, co-authored, and edited the manuscript.

- S-T. J. Tsang and A. H. R. W. Simpson are joint first authors.

Funding statement:
- There were no funding sources involved in the creation of this editorial. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

ICMJE COI statement
- The authors declare that there are no conflicts of interest.

Ethical review statement:
- Research Ethics Committee approval was not required for this editorial.